• Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”)
• The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs
• Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more
• According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success

In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners with third-party companies looking to explore formulation opportunities with their targeted APIs, out-licenses its technology, and is actively developing lead product candidates. According to a 2021 video, the company also hopes to provide a lifeline to pharmaceutical companies noting that DehydraTECH(TM) “may provide additional patent extensions for existing drugs, which is a potential billion-dollar insurance policy to original drug manufacturers” (https://ibn.fm/qItAF). So named because it features a dehydration synthesis procedure, the DehydraTECH technology has been found to improve bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”). To discover more about the effectiveness of DehydraTECH, Lexaria has studied the DehydraTECH processing of various APIs, most recently the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil – whose most widely known product available for sale is Viagra(R) – for potential application in the management of erectile dysfunction. The animal study revealed that DehydraTECH resulted in faster and higher overall delivery of sildenafil into the bloodstream (https://ibn.fm/VYdtO) than concentration-matched controls. Valued at $4.99 billion in 2021, the erectile dysfunction drug market is expected to grow at a CAGR of about 4.6% between 2021 and 2025, reaching $5.97 billion (https://ibn.fm/pRAKd). Other DehydraTECH markets being evaluated by Lexaria include the broader cannabidiol (“CBD”) market, which is projected to grow at a 51% CAGR from a value of $2.7 billion in 2021 to approximately $111 billion by 2030 (https://ibn.fm/eLpuv). CBD is increasingly used in a myriad of applications that Lexaria is equally targeting. The company recently announced it had begun the first phase of its epilepsy animal research to evaluate the seizure-inhibiting activity of DehydraTECH-CBD compared to Epidiolex(R), the sole FDA-approved CBD-based seizure drug (https://ibn.fm/Q6rLN). The global epilepsy market, valued at $10.3 billion in 2020 and 10.6 billion in 2021, is projected to grow to $12.9 billion in 2026 and $16.6 billion by 2031 (https://ibn.fm/qUPGW). In addition, Lexaria is evaluating DehydraTECH-CBD as a potential treatment for hypertension, announcing late last year it had received an Independent Review Board (“IRB”) approval ahead of schedule for its fourth DehydraTECH-CBD human hypertension study, HYPER-H21-4, tentatively set to begin this month (https://ibn.fm/0VRcd). HYPER-H21-4 will build on previous human and animal research, which demonstrated that DehydraTECH-processed CBD results in a rapid and sustained drop in blood pressure and reduces arterial stiffness. The World Health Organization reports that an estimated 1.28 billion aged between 30 and 79 years have hypertension. But, of concern, only about 1 in 5 persons have it under control (https://ibn.fm/zDYwM). DehydraTECH-CBD could therefore provide patients the much-needed reprieve, enabling Lexaria to also tap into the global hypertension drugs market expected to grow at a CAGR of 3.4% from a value of $24.4 billion in 2020 to $31.5 billion by 2028 (https://ibn.fm/HdOkS). Lexaria has also evidenced faster and more effective delivery of DehydraTECH-processed nicotine. Results from an animal study, the NIC-A21-1, announced last fall, showed that DehydraTECH-oral nicotine peaked in the bloodstream 10x to 20x faster than controls. At the same time, the peak levels achieved were up to 10x higher than controls. Valued at $59.8 billion in 2021, the global nicotine replacement therapy market is expected to reach $147.9 billion by 2028, growing at a 16.3% CAGR (https://ibn.fm/gAxgQ). “We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $1 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success: if any one single area of investigation were to fail, we want to ensure we still have other opportunities to exploit,” wrote Lexaria CEO Chris Bunka in an annual letter to stakeholders (https://ibn.fm/VLw0X). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• LiDARs have been one of key enablers for autonomous vehicle sector, but this unique technology offers use cases beyond automotive industry
• Consumer Electronics Show, one of the world’s most influential tech events, demonstrates that LiDAR is growing within non-automotive landscape, including smart city/infrastructure and security
• Cepton set to benefit as the Company has already established its presence in non-automotive, delivering LiDAR systems for smart cities, spaces, and industrial applications around the globe

Cepton (NASDAQ: CPTN), a Silicon Valley leader in innovative, high-performance LiDAR solutions, appears well-positioned to benefit as the non-automotive applications of the LiDAR technology grow. LiDAR technology seems to be on its path to move away from the realm of sci-fi-like promises toward real applications and commercialization. While the autonomous vehicle sector strives to make strides in terms of a safe and sustainable driving experience, for which LiDARs are one of the key enablers, the question remains as to what the future holds for this technology beyond the automotive sector? If the latest Consumer Electronics Show (“CES”) is anything to go by – and it should be, as the event prides itself on being the most influential tech happening in the world – LiDAR has grown in importance not only for the automotive sector but also for non-automotive applications. The latter includes smart city/infrastructure and security, which are becoming increasingly important for LiDAR producers. These applications require top-notch 3D image processing and actionable perception software, where LiDARs can shine (https://ibn.fm/BblKI). As a pioneer in the LiDAR space, Cepton has already been riding the rising non-automotive wave, collaborating with global partners to transform transportation infrastructure, public venues, and large commercial facilities using innovative LiDAR solutions. For example, in 2020, the Company partnered with The Indoor Lab in a pilot project at an Orlando International Airport terminal. The aim of the project was to deliver anonymous footfall tracking through a LiDAR-based crowd analytics solution to assist travelers in avoiding crowded areas and maintenance crews in targeted cleaning (https://ibn.fm/dPcPB). In addition, last year, Cepton joined the Qualcomm Smart Cities Accelerator Program in a bid to advance the future of smart infrastructure with their LiDAR systems. And most recently, Cepton engaged in developing a LiDAR-based vehicle detection system to help build city-wide smart transportation infrastructure in South Africa’s Cape Town which will provide authorities with analytics designed to improve traffic flow and safety for drivers and pedestrians (https://ibn.fm/cBk7D). With a product portfolio diversified across both automotive and non-automotive spaces, Cepton seems to be well-positioned to leverage a variety of intelligent sensing applications in markets outside of automotive. As the Company continues to employ its proprietary solutions designed to provide accurate, real-time, and anonymized 3D perception, it appears poised to make its footprint in the global landscape to transform smart cities, spaces, and industrial applications. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential
• InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products
• The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year
• The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions, including glaucoma and a severe genetic skin disorder known as epidermolysis bullosa (“EB”)

Rare cannabinoid drug developer InMed Pharmaceuticals (NASDAQ: INM) is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year to better approach the pharmaceutical and health and wellness markets (https://ibn.fm/9B9dG). InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (“CBC”) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (“CBT”) to the health and wellness market on a B2B basis according to a company news release, so revenues from those sales would appear in future quarterly reports (https://ibn.fm/feLVe). The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates sales of cannabidivarin (“CBDV”) and tetrahydrocannabivarin (“THCV”) in the coming months as its next revenue generators. A Harvard Medical School report noted THCV has some “exciting” potential in treating obesity and diabetes because of its apparent capacity to reduce fasting insulin levels, enhancing weight loss and improving glycemic control, which has been demonstrated in animal trials but is without human studies to support it thus far (https://ibn.fm/MQbIs). CBDV is being considered as a potential means of modulating “brain excitatory-inhibitory systems” — including its possibilities for treating the irritability in autistic children (https://ibn.fm/rEyIq). “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand,” BayMedica SVP and General Manager Shane Johnson stated in January (https://ibn.fm/d92LZ). “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors.” The company expects to produce more than 100 kilograms of CBDV and THCV under the initiative. Because of the very limited quantities of rare cannabinoids that make them effectively impractical from an economic standpoint to extract directly from the plant for pharmaceutical use, InMed’s R&D operation is working to develop synthetic formulations for the treatment of specific conditions. INM-755, a cannabinol (“CBN”) topical cream under clinical development for the treatment of a severe genetic skin disorder known as epidermolysis bullosa (“EB”), is undergoing patient screening and treatment in a Phase 2 clinical trial at 13 sites in eight European countries following two Phase 1 clinical trials in healthy volunteers. The company reports it is the first time a CBN-based formulation has ever advanced to a Phase 2 clinical trial (https://ibn.fm/WAefY). InMed is also developing a CBN formulation for the potential treatment of glaucoma. INM-088 dosing is currently being researched for topical delivery to the eye as a means of reducing intraocular pressure and providing neuroprotection of the eye. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• InnerScope Hearing Technologies recently announced that subsidiary HearingAssist’s products would be carried by RiteAid.com
• The distribution agreement with one of the nation’s leading drug store chains comes as InnerScope seeks to position itself to benefit from the upcoming OTC Hearing Aid Law
• The Hearing Aid Law will create a new category of hearing aids, available from any retailer without need of doctor appointments or fittings.
• The law will also see the average cost of these hearing aids decline significantly relative to their current cost – allowing for greater access from the over 40 million Americans unable to afford the product

InnerScope Hearing Technologies (OTC: INND), a disruptive manufacturer and distributor/retailer of direct-to-consumer and FDA registered Bluetooth-controlled hearing aids and personal sound amplifier products (“PSAPs”), recently announced that subsidiary HearingAssist would be launching its branded hearing products and related supplies on RiteAid.com. The announcement will mark yet another milestone for HearingAssist, a long-established leader in the direct-to-consumer hearing aid market, with the company having sold over 500,000 hearing aids since 2008 and generated upwards of over $72 million in top-line revenues from 2018 to 2021 whilst simultaneously transforming into Walmart’s largest hearing aid supplier in the process (https://ibn.fm/Bnm1E). In October 2021, the FDA proposed its initial guidelines for the ground-breaking Over-The-Counter (“OTC”) Hearing Aid Law (“OTC Hearing Aid Law”); will see a new category of hearing aids created, which will be available from any seller without doctor appointments or fittings, and sold at a fraction of the typical cost – about $600 per pair instead of the average $5,000 (which includes fittings and follow-up services) (https://ibn.fm/JNgHY). In anticipation of the upcoming OTC Hearing Aid Law, the management teams at HearingAssist and InnerScope have sought to forge relationships with major retailers and pharmacy chains, seeking to establish and promote its product portfolio ahead of a potential roll-out across their partners’ in-store locations and websites. The successful placement of HearingAssist products on RiteAid.com, one of the nation’s largest drugstore chains with stores in 17 states across the United States, is an early affirmation of the company’s ongoing strategy – one which has already seen the company roll-out its products across their www.iHearDirect.com e-commerce website as well as on the likes of FSAStore.com, HSAStore.com, and WellDeservedHealth.com. “The management teams of HearingAssist and InnerScope are proud to offer HearingAssist Products for all Rite Aid customers,” stated Matthew Moore, President and CEO of InnerScope Hearing Technologies. “The launch of HearingAssist Products on RiteAid.com increases InnerScope’s and HearingAssist’s market penetration and brand recognition ahead of the OTC Hearing Aid Law” (https://ibn.fm/NiXVt). The RiteAid.com win follows on the heels of a number of operational highlights achieved by the company in recent months. In early October, InnerScope announced that it had acquired iHEAR Medical Inc, a direct-to-consumer hearing solutions provider, providing InnerScope with access to over 40 patents and an FDA-registered manufacturing and R&D facility in the process. The company subsequently presented its preliminary fourth quarter 2021 results, with revenues of $633,894 for the year’s final three months (https://ibn.fm/hBIRI) – a record result that coincided with InnerScope’s HearingAssist receiving purchase orders from Walmart of nearly $280,000. (https://ibn.fm/3WoOY). A recent White House fact sheet revealed that the elevated cost of hearing aids permitted a mere 14% of the approximately 48 million Americans with hearing loss to afford the life-changing product (https://ibn.fm/pEwQI). A heavily concentrated marketplace – with the four largest hearing aid manufacturers controlling upwards of 84% of the market – has also contributed to the elevated pricing for the devices. Now and with the forthcoming OTC Hearing Aid Law set to disrupt the decades-long status quo for the hearing aids market, InnerScope will seek to leverage upon its hugely disruptive, direct-to-consumer model to revolutionize the hearing aid market once and for all. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.iHearDirect.com NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

At the juncture of a socio-economic revolution, Africa is open to new opportunities and possibilities forthcoming in the global blockchain ecosystem. Keeping in mind the scope and interest in blockchain and cryptocurrency in the region, Bitcoin Events organized the 2nd virtual and 8th annual edition of the Blockchain Africa Conference on March 17-18th, 2022. The Blockchain Conference witnessed 1964 attendees from 113 countries, on a forum shared by 57 speakers and dignitaries who expressed their views on the business scope of blockchain in Africa. Participants leveraged the virtual conference floor to connect with peers and attended the knowledge-packed 57 sessions to understand the avenues and developments in the African and global blockchain ecosystem. The Bitcoin Event conferences offer a viable avenue for new and established entities to explore opportunities in the Bitcoin, cryptocurrency, and Blockchain industries. Many eminent dignitaries graced the event to discuss important issues on the social, economic, and financial aspects of the global cryptocurrency economy. Industry veteran, Dr Edward Obasi, COO at DafriGroup PLC, expressed his views, “Blockchain technology is increasingly advancing socio-economic growth for E-commerce and entrepreneurship in Africa and the rest of the globe. The adoption of blockchain and cryptocurrency technologies offer users multiple options and scalability towards ease of doing business.” John Kamara, Founder of Adanian Labs and Afyarekod, and Chairman of the African Blockchain Centre resided as the Master of Ceremonies of the conference and welcomed all the guests, presenters, and speakers and sponsors. He went on to credit Bitcoin Events for hosting the event and doing a phenomenal job of spreading awareness about bitcoin trading and encouraging networking, in the community as well as on a global level. The two-day event offered an exciting avenue for insights, debates, and panel discussions to discuss the future of blockchain and whether this ecosystem is ready to make its way into mainstream businesses. Post-event recordings of the conference sessions are available on our YouTube channel (https://ibn.fm/66qBl), and the overview of the conference is available on our website (https://ibn.fm/l19ad). To continue being a part of the blockchain events, interested individuals/entities can attend the upcoming events:

• 4th edition of the Crypto Fest (29 September 2022 in Cape Town)
• 3rd edition of the DeFi Conference (date to be confirmed in late 2022 and will be hosted virtually)
• 9th edition of the Blockchain Africa Conference (March 2023 in Johannesburg, South Africa)

To learn more, please visit https://ibn.fm/l19ad.

• Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging.
• Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being.
• Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics.

Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin CEO Doug Drysdale. “Until now, our understanding of the psychedelic experience has been fairly subjective. This study may lead to larger studies that have the potential to bridge the gap between bringing psychedelics to therapeutics as we learn more about the advantages of these important molecules on brain activity and overall mental well-being.” Cybin, a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), received U.S. Food and Drug Administration Investigational New Drug authorization last year and Institutional Review Board approval earlier this year for the study, which is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/WISGk). During the study, participants will wear the Kernel Flow headset while receiving either a low dose of ketamine or a placebo. The Kernel Flow device, which features hi-tech sensors to record brain activity, will monitor the participants before, during and after receiving the substances. Additional information will be obtained from structured questionnaires and validated assessments that will be gathered from the participants during study visits and a follow-up. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Drysdale. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics.” Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules
• The world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemic
• Mydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT markets – with potential growth across all avenues

In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”) brief released in March 2022 (https://ibn.fm/NIX0U). The brief also highlights who has been most affected and summarizes the pandemic’s effect on the availability of mental health services. Data compiled by the WHO, including statistics from the latest Global Burden of Disease study, identifies young people and women as the most vulnerable populations for mental health disorders at the hand of the pandemic – with young people carrying a disproportionate risk for suicide or self-harming behavior. The WHO pointed out in their brief that there is a shortage of mental health resources globally which extends to the present. The most recent WHO Mental Health Atlas shows that in 2020, governments worldwide spent an average of 2% of their health budgets on mental health, with low-income countries reporting less than one mental health worker per 100,000 people. Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) was founded in 2020 as a response to the lack of innovation addressing mental health treatment. Mydecine is currently developing innovative first- and second-generation novel therapeutics to treat the unmet need in mental health and addiction disorders. The company focuses on psychedelic compounds and other novel molecules with therapeutic potential. There is increased focus on the therapeutic potential of psychedelic drugs, as the market is expected to gain momentum and expand from an estimated value of $2.82 billion in 2022 to approximately $7.57 billion by 2028. Driving factors of growth in this market include the rising prevalence of mental depression and anxiety, in addition to the availability of off-label drugs, which have propelled the demand for psychedelic drug options within the market (https://ibn.fm/c0rfm). Mydecine also targets mental health disorders like Post Traumatic Stress Disorder (“PTSD”). In 2020, the global market for PTSD therapeutics was valued at $2.3 billion. By 2027, this market is expected to grow to $3.1 billion, growing at a CAGR of 4.3% over the forecast period (https://ibn.fm/H6UF2). The company’s current pipeline consists of drug candidates that provide a variety of enhancements and are part of psychedelic-assisted therapy programs which are in clinical trial or pre-trial stages as potential treatments for PTSD and smoking cessation. Mydecine’s wholly-owned subsidiary Mindleap features a platform that is the first international virtual health platform that includes psychedelic integration. Mindleap provides features for introduction and post-care integration, including:

• Fact-based education
• 1:1 video coaching
• Trustworthy content
• Wellness guidance
• Built-in health journal

Mindleap is leveraging a global healthcare IT market valued at $74.2 billion in 2020. This market is expected to grow at a CAGR of 10.7% over the forecasted period (https://ibn.fm/UqtsZ). The increased adoption of preventative care, more funding for health startups, growing network coverage, improved infrastructure, and advancements in technology, are all contributing market growth factors. The Mindleap healthcare platform is available for iOS and Android download today in the app store (www.Mindleap.com). For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Correlate Infrastructure Partners is a provider of data analysis and scalable services to help commercial and industrial real estate owners meet carbon reduction goals while also improving their net operating income
• Carbon reduction is a significant part of the multi-national response to climate change concerns, and Correlate Infrastructure Partners is taking a site-specific approach to furthering goals established worldwide in 2015
• The company has been known as Triccar, but its stockholders approved changing the company name and ticker symbol in February, with final approval from the SEC expected within the coming days
• The company’s efforts to redefine itself reflect its recent acquisition of Correlate Inc. and Loyal Enterprises LLC (dba Solar Site Design) — subsidiaries that together help provide clients with green energy consumption solutions

Worldwide governments and many industry leaders are racing to reduce a steady increase in global temperatures, referred to as climate change, amid concerns about the change’s effect on life and the standards of living humanity expects for itself. But “despite growing pledges of climate action, global emissions are at an all-time high,” according to a statement by United Nations Secretary-General António Guterres on March 31 (https://ibn.fm/WFd8n). “To avert a climate catastrophe, we need bold pledges but matched by concrete, measurable action,” Guterres added. In 2015, 196 members of the international community reached agreement on climate change, setting goals to keep global temperatures from rising 1.5 degrees Celsius above pre-industrial levels – a level regarded as critical by many in answer to the life quality concerns. The UN’s Statistics Division has reported that in order to meet the goals, global carbon dioxide emissions need to be reduced by 45 per cent by 2030 from 2010 levels, and reach net-zero emissions by 2050 (https://ibn.fm/4XOm7). Green facilities electrification solutions provider Correlate Infrastructure Partners (OTCQB: TCCR) is dedicated to helping commercial and industrial real estate owners meet carbon reduction goals in such a way that they are simultaneously able to improve net operating income at significant levels. Correlate Infrastructure Partners believes there is a large market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale. The company is at a key inflection point of its growth, having completed acquisition of 100 percent of the equity of Correlate Inc. and Loyal Enterprises LLC (dba Solar Site Design) shortly before the start of the year. In February, the company’s stockholders approved renaming the business to Correlate Infrastructure Partners and abandoning its earlier identity, Triccar. The company filed the information with the U.S. Securities and Exchange Commission (SEC), seeking a new ticker symbol as well. The company also expects to file its annual report on Form 10-K within the very near future (https://ibn.fm/0UnrG). Through its subsidiaries, Correlate Infrastructure Partners uses data in proprietary analytics, concierge subscription services and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs without upfront capital, while also connecting the commercial solar industry with the tools it needs to acquire project opportunities and prospective clients with the expertise they need to design and finance their projects according to their needs. The smart use of building utilities is a key way to reduce wasteful behaviors that lead to unnecessary energy consumption. After comparing utilities and facility data with energy use goals, Correlate Infrastructure Partners helps to identify areas of opportunity for reducing consumption through its analytics expertise and, ultimately, how to maintain the improvements it delivers. For more information, visit the company’s website at www.CorrelateInfra.com. NOTE TO INVESTORS: The latest news and updates relating to TCCR are available in the company’s newsroom at https://ibn.fm/TCCR

• Michigan continues to break sales records in the cannabis sector
• ACP currently operates in Michigan and California and is exploring strategies for expanding operations to two more states
• The company is focused on three business segments: real estate, acquisition and development of proprietary assets, and ongoing cultivation operations

Cannabis sales numbers for December 2021 are in, and Michigan has broken another record (https://ibn.fm/pySD7). This is the kind of news that cannabis operators in the state, including American Cannabis Partners (“ACP”), love to hear. “Michigan closed out 2021 with another record-breaking month of adult-use marijuana sales in December, state officials say,” reported a recent “Marijuana Moment” article. “The state saw more than $135 million in recreational cannabis purchases and about $33 million in medical marijuana sales last month. “Andrew Brisbo, executive director of the Michigan Marijuana Regulatory Agency (‘MRA’), said on Monday that the numbers ‘marked another high for the adult-use industry,’” the article continued. “The previous adult-use marijuana sales record happened in October, with about $128 million in purchases.” Brisbo went on to note that the “new high is not because of increasing prices. . . . In fact, prices in medical and adult-use continue to drop, month over month and year over year.” The article observed that, while December set the new record for adult-use marijuana purchases, the state saw the most combined recreational and medical cannabis sales in July, with sales totaling about $171 million. “The latest data brings Michigan’s total cannabis sales for 2021 to $1,311,951,737 for adult-use and $481,225,540 for medical marijuana. And those purchases are translating into hundreds of millions of dollars in tax revenue for the state,” the article concluded. “About $131 million is going to a cannabis excise tax fund that supports various initiatives such as infrastructure and public education, MRA spokesman David Harns said. Another $115 million will support the state general fund.” ACP currently operates in Michigan and California. The company is also in the process of exploring land acquisition and project development strategies for expanding operations to two more states this year. With a total of 12 cannabis licenses, including 560,000 square feet of cultivation licenses in California and Michigan and one retail license in Michigan, ACP is committed to becoming a leader in the U.S. cannabis industry. The company is focused on three business segments: real estate, acquisition and development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with more than three decades of canna-business experience, ACP is guided by its strategy to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on federal interstate commerce opportunities. Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference
• In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year
• During a recent interview on The Jesse Tee Show, Stang noted the company intends to scale its ketamine clinics as well as build infrastructure to accommodate expanded psychedelic healing
• The company hopes to utilize its expanded infrastructure to help destigmatize mental health conditions

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a company on a mission to provide research, high-quality products, education, and effective treatment options and reframe the psychedelic conversation, recently revealed its Co-founder and CEO, Matt Stang, will take part in a series of upcoming investor conferences scheduled for this spring (https://ibn.fm/PgYbu). Staggered between April and May, the events will see Stang share the company’s new revenue lines and strategic outlook for the rest of the year. At the 10th Annual Scottsdale Capital Event, scheduled for April 22-24, Stang will participate in one-on-one meetings that will look into Delic’s strategic outlook for the rest of the year. Hosted by Capital Event Management at the Fairmont Scottsdale Princess Resort in Scottdale, Arizona, the three-day event is designed to provide institutional investors, high net worth individuals, portfolio managers, and investment advisors to listen to growing companies’ stories and subsequently invest (https://ibn.fm/H4hF1). On May 4, Stang will present at the Planet MicroCap Showcase, a leading in-person event in MicroCap Finance. Stang’s presentation will focus on Delic’s business outlook and growth opportunities for the second half of the year. Like the Scottsdale Capital Event, the three-day Planet MicroCap Showcase, set to be held in Las Vegas, is expected to bring together the premier dealmakers and the most promising organizations. Closing out the series of events is the H.C. Wainwright Annual Global Life Sciences Conference, a hybrid event to be held in Miami, Florida, from May 23 through May 26. During a scheduled presentation, whose recording will be availed from June 10, Stang will detail Delic’s expansion strategy and industry outlook. He will also take part in one-on-one meetings. The common theme of Stang’s presentations and one-on-one meetings is Delic’s growth throughout the remainder of the year. And during a recent interview on The Jesse Tee Show, Stang offered a glimpse into this outlook, possibly pointing to what attendees are likely to hear. When asked about the direction he anticipates Delic to take, for example, Stang discussed the fact that the company seeks to scale (https://ibn.fm/ak4U8). “Being the largest clinic chain in America today, [we look to grow] that exponentially over the next couple of years. We think that the real opportunity is to be in the top 50 or top 100 markets with the clinics, where [people] can get safe, effective, and beneficial care. We want people to feel like there is a solution in their backyard,” said Stang. “The opportunity is to build this thing to a scale where you will see one of our clinics somewhere within 30 minutes of you.” Delic owns and operates an umbrella of brands, including Ketamine Wellness Centers (“KWC”), which constitute the United States’ largest retail and physical footprint of ketamine clinics. While the clinics currently focus on treating mental health conditions using ketamine infusions, Stang noted the company’s outlook for the future also considers other new treatment options, including psilocybin and MDMA (ecstasy), two psychoactive drugs likely to be approved by the Food and Drug Administration (“FDA”) in the coming years, according to a report by the New York Times (https://ibn.fm/nXclX). Additionally, the company intends to build the infrastructure for psychedelic healing, enabling it to effectively adopt better treatments as new molecules are developed and approved. “Each person is so individual and different, and I think having a larger number of [psychedelic treatment options] to try – and they are all so powerful and beneficial in their own ways – is going to change how people interact with and talk about mental health. We can destigmatize mental health conditions,” Stang continued. As part of his presentations during the upcoming investor conferences, Stang is likely to reiterate these sentiments, constraining his outlook to 2022. This is expected to offer insights that could potentially influence investors’ investment in the fast-growing company. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF